Core Viewpoint - Tianchen Medical (688013) has experienced a slight decline in stock price, closing at 48.03 yuan, down 0.1% from the previous week, with a current market capitalization of 3.898 billion yuan [1] Group 1: Company Announcements - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) Co., Ltd. on December 31, 2025, focusing on medical intelligence and information technology, smart medical devices, and market collaboration [2] - The company held its first extraordinary shareholders' meeting of 2026 on January 7, 2026, where the board of directors was re-elected, and new directors were appointed [2][3] - The company announced a change in the quality control reviewer for the 2025 audit from Wang Wei to Jiang Ming, who has relevant professional qualifications and no disciplinary records in the past three years [3][4] Group 2: Board Restructuring - The board of directors completed its re-election, with Chen Wangyu elected as chairman and continuing as general manager, while Tian Guoyu was appointed as financial director and board secretary [3][4] - The new board consists of three non-independent directors, three independent directors, and one employee representative director [3]

Core Viewpoint - The company has signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) Co., Ltd. to promote innovation and industrialization in medical intelligence and information technology [1] Group 1: Cooperation Details - The cooperation aims to advance intelligent manufacturing of medical devices and consumables, as well as the research and production of medical robots [1] - Key areas of collaboration include medical intelligence and information, smart medical devices, medical robots, market synergy, and brand co-construction [1] Group 2: Agreement Impact - The agreement is effective upon the affixing of official seals by both parties and is expected to guide long-term cooperation [1] - It is anticipated that the agreement will not have a direct impact on the company's performance for the fiscal year 2026 and beyond [1]